Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary disease (COPD) by Young, Jane S. et al.
Cochrane Database of Systematic Reviews
Interventions to promote referral, uptake and adherence to
pulmonary rehabilitation for people with chronic obstructive
pulmonary disease (COPD) (Protocol)
Young J, Jordan RE, Adab P, Enocson A, Jolly K
Young J, Jordan RE, Adab P, Enocson A, Jolly K.
Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for peoplewith chronic obstructive pulmonary disease
(COPD).
Cochrane Database of Systematic Reviews 2017, Issue 10. Art. No.: CD012813.
DOI: 10.1002/14651858.CD012813.
www.cochranelibrary.com
Interventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary
disease (COPD) (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
11APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
14SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iInterventions to promote referral, uptake and adherence to pulmonary rehabilitation for people with chronic obstructive pulmonary
disease (COPD) (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Interventions to promote referral, uptake and adherence to
pulmonary rehabilitation for people with chronic obstructive
pulmonary disease (COPD)
Jane Young1 ,2, Rachel E Jordan2, Peymane Adab2, Alexandra Enocson2 , Kate Jolly2
1Senior Lecturer in Community Nursing, School of Nursing and Midwifery, Anglia Ruskin University, Cambridge, UK. 2Institute of
Applied Health Research, University of Birmingham, Birmingham, UK
Contact address: Jane Young, Senior Lecturer in Community Nursing, School of Nursing and Midwifery, Anglia Ruskin University,
Cambridge, UK. jane.young@anglia.ac.uk.
Editorial group: Cochrane Airways Group.
Publication status and date: New, published in Issue 10, 2017.
Citation: Young J, Jordan RE, Adab P, Enocson A, Jolly K. Interventions to promote referral, uptake and adherence to pulmonary
rehabilitation for people with chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2017, Issue 10.
Art. No.: CD012813. DOI: 10.1002/14651858.CD012813.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the effectiveness of interventions to increase patient referral, uptake, and adherence to pulmonary rehabilitation pro-
grammes, for patients with COPD.
B A C K G R O U N D
Description of the condition
Chronic obstructive pulmonary disease (COPD) is defined as ‘a
common, preventable, and treatable disease that is characterised
by persistent respiratory symptoms and airflow limitation that are
due to airway or alveolar abnormalities (or both), usually caused
by significant exposure to noxious particles or gases’ (Vogelmeier
2017).
Burden of disease
COPD is a common and increasingly prevalent respiratory dis-
ease that presents major public health challenges worldwide
(Lopez-Campos 2016). It accounts for 2.9 million deaths world-
wide annually, and is currently the third leading cause of global
death (Lozano 2012). It is estimated that 328 million people have
been diagnosed with COPD worldwide (Lopez-Campos 2016),
but it is accepted that this may represent less than half of the true
disease burden, as there are many undiagnosed people living with
COPD (Bernd 2015).
COPD accounts for high healthcare utilisation and subsequent
cost worldwide (Lopez-Campos 2016). Emergency hospital ad-
missions for COPD exacerbations are rising annually (Steiner
2015), although timely communitymanagement can reducemany
COPD emergency hospital admissions (Blunt 2013).
Risk factors for COPD
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Tobacco smoke is the largest risk factor for COPD, although other
factors, including outdoor air pollution, the burning of biomass
fuels, exposure to passive smoking and other noxious gases and
fumes, combined with genetic disposition, maternal tobacco ex-
posure, and childhood respiratory infections, are important con-
tributors to disease development. Increased exposure to risk factors
for COPD (with the rising tobacco epidemic in low- and middle-
income countries) and increasing population longevity contribute
to the heavy forecasted societal and economic burden worldwide
(Lopez-Campos 2016).
Pathology, symptoms, and progress
The pathophysiological effects of COPD are chronic inflamma-
tion of the airways and irreversible lung tissue damage, resulting
in reduced airflow to the lungs (Szilasi 2006). COPD is diag-
nosed when spirometry demonstrates airflow obstruction that is
not fully reversible (Qaseem2011). COPD is a debilitating disease
that worsens over time, with frequently reported symptoms of de-
creased exercise capacity, dyspnoea, and leg fatigue (Butcher 2012;
Houchen 2009). Patients may experience exacerbations, when the
symptoms of their disease worsen in response to stimuli, such
as respiratory infections and air pollution (Anzueto 2007; White
2003). The frequency of exacerbations is variable, but tends to
increase as the disease progresses (Hoogendoorn 2010). Exacerba-
tions are one of themain causes of worsening prognosis, often lead-
ing to hospital admission, particularly for those with severe dis-
ease (Anzueto 2007). Hospital admission in those with COPD is
associated with poor prognosis, lower quality of life, high post-ad-
mission mortality, and high 90-day re-admission rates (Alamagro
2010; Anzueto 2007; Steiner 2016).
Comorbidities
COPD co-morbidities are common, and include cardiovascular
disease, diabetes, asthma, anxiety, and depression (Eisner 2010;
Mannino 2015;Schneider 2010). These increase the overall bur-
den to the individual, as well as to families, caregivers, and health
and social care services, a burden that is increasing worldwide
(GBD 2015).
COPD Management
Other than the treatment and prevention of exacerbations, therapy
during stable COPD is aimed at reducing progression and man-
aging symptoms. All patients should be offered smoking cessation
advice at regular intervals, as this is the main disease-modifying
treatment available at present (Vogelmeier 2017). Pharmacother-
apy consists of short-acting and long-acting bronchodilator in-
halers, with steroid inhalers added to manage symptoms and pre-
vent exacerbations. Patients with more severe breathlessness (usu-
ally Medical Research Council (MRC) Grade 3 or worse, dysp-
noea) are eligible for pulmonary rehabilitation (PR). All patients
should receive influenza and pneumococcal vaccines, and advice
about self-management (Bolton 2013; Vogelmeier 2017). In prac-
tice, evidence from the literature suggests that patients are often
not appropriately managed, with over and under prescription of
inhalers, and under-utilisation of other effective services (Perez
2011; Price 2014).
Details of pulmonary rehabilitation
Pulmonary rehabilitation (PR) is a structured multidisciplinary
programme defined as ‘an interdisciplinary programme of care for
patients with chronic respiratory impairment that is individually
tailored and designed to optimise each patient’s physical and so-
cial performance and autonomy. Programmes comprise individ-
ualised exercise programmes and education’ (Bolton 2013). One
of the main aims of PR is to increase physical activity for those
with COPD (Spruit 2013). Increasing physical activity requires
behaviour change. PR emphasizes behaviour change through pa-
tient and interdisciplinary collaboration, and it is this collabora-
tive approach that is key in achieving increasing physical activity
in patients with COPD, over exercise-only interventions (Spruit
2015). PR programmes are commonly delivered to groups of pa-
tients in community or hospital settings, although other mod-
els of delivery, including home-based programmes, are also avail-
able. Evidence that supports home-based PR as an alternative, yet
effective PR approach for COPD patients, is an emerging field
(Grosbois 2015; Mohammadi 2013).
Recommendations state that for optimal effectiveness, pro-
grammes should run twice weekly for a minimum of six weeks
(Bolton 2013; Vogelmeier 2017), although programmes that run
twice weekly for a minimum for eight weeks are recommended by
other guidelines (Rochester 2015).
Randomised controlled trials (RCTs) show that PR is effective in
improving exercise capacity, breathlessness, functional indepen-
dence, and psychological well-being (McCarthy 2015; Zoeckler
2014). PR also reduces healthcare utilisation, including hospital
admissions and length of stay (California PRC Group 2004; Hui
2003). The effect on hospital admission appears to be related to
the comprehensiveness of individual programmes, which is often
variable (Moore 2016; Puhan 2016). Economic analyses suggest
it is also cost-effective, at GBP 2000 to GBP 8000 per Quality-
Adjusted Life Year (QALY), thus overall, it is an essential compo-
nent in the management of COPD (Williams 2011).
Referral to PR
The American College of Physicians, American College of Chest
Physicians, American Thoracic Society, and European Respiratory
Society COPD clinical guidelines recommend PR for all symp-
tomatic COPD patients with a Forced Expiratory Volume in one
second (FEV1) less than 50% predicted (Qaseem 2011). Recom-
mendations are that PR is undertaken at a time of disease stability
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(Bolton 2013; Rochester 2015; Vogelmeier 2017), yet undertak-
ing PR soon after an acute exacerbation of COPD is clinically
valuable (Rochester 2015), particularly when hospitalisation for
an exacerbation was required (Bolton 2013; Puhan 2016).
In European countries, most referrals to PR are undertaken by
healthcare practitioners from primary, community, secondary, and
tertiary care settings, whilst in North America, self-referral is rel-
atively common (Spruit 2014). Referral to PR remains persis-
tently poor worldwide, regardless of the availability of PR (Camp
2015; McNaughton 2016; Steiner 2015; Wadell 2013). In their
New Zealand audit, McNaughton 2016 reported that only 2%
of the expected COPD population was referred to PR, whilst in
England and Wales, 68,000 (15.2%) of 446,000 eligible patients
were referred (Steiner 2015). Reasons given for low patient refer-
ral by healthcare practitioners included a lack of knowledge about
programme content, challenging or uncertain referral process (or
both), time pressures for the prospective referrer, uncertainty of
whose role it was to refer, and anticipated access difficulties for pa-
tients (Foster 2016; Harris 2008a; Johnston 2013). Conclusions
from these studies were that these difficulties disempowered the
healthcare practitioner (HCP), and that increasing knowledge of
PR and its benefits would improve referral rates.
Attendance at pulmonary rehabilitation
Following referral, patients are required to attend a PR pre-assess-
ment. This is commonly completed by the PR staff and includes
a full patient history, physical examination, assessment of con-
traindications and risk factors, such as unstable cardiovascular dis-
ease (unstable angina, unstable arrhythmias, aortic aneurysm, hy-
pertension), or other inhibiting conditions, such as severe arthritis
or neurological conditions (Bolton 2013; Spruit 2013). It is also
a time during which a detailed description of the programme is
provided, and discussions about individual patient goals, motiva-
tions, expectations, including barriers and capabilities, should be
discussed (Vogelmeier 2017).
In the England andWales audit, it was reported that of the 68,000
COPD patients referred, 47,020 (69%) attended pre-assessment,
following which, 10% to 14.8% of patients did not enrol in PR
(Steiner 2015; Steiner 2016). Keating 2011 reported that uptake
of PR has traditionally been poor, with up to half of the patients
offered a course, not enrolling. Reasons for patients’ lack of uptake
or attendance at PR included limited understanding of COPD
and a high COPD symptom burden, leading to fear and a sense
of loss of control (Harris 2008b; Lewis 2014). Consequently, PR
is often perceived as too difficult to complete, of limited benefit,
or both (Cooke 2012; Hayton 2013; Keating 2011). Additional
influencing factors include the referrer (Arnold 2006;Hogg 2012),
and transport difficulties, including access to transport and cost
of travel (Almadana 2014; Keating 2011).
Patients decline to attend pulmonary rehabilitation at the initial
assessment stage, the first PR session, or both (Cassidy 2014;
Keating 2011). Following assessment, some COPD patients are
deemed ineligible for PR, and in other cases, the patient themselves
chooses to decline. However, the assessment of contraindications,
including unstable angina, can often be subjective (Gunes 2009).
Standardising this assessment would reduce current variation and
ambiguity between guidelines (Bolton 2013; Spruit 2013).
PR adherence
Studies report variable and un-sustained attendance following en-
rolment in a PR course, with non-completers ranging from 42%
inKeating 2011 to 58% in Steiner 2016. A Swedish audit reported
PR completion rates ranging between 20% and 99% (Wadell
2013).
PR adherence reporting measures vary across studies. For example,
Hayton 2013 reported that 71% of patients attended at least 63%
of the planned eight sessions, and an audit inNewZealand showed
that 46% to 75% of attendees attended all 16 planned PR sessions
(McNaughton 2016).
Factors associated with lower attendance include advancing age,
being female, being from a minority ethnic group, being a current
smoker, having greater breathlessness, living alone, experiencing
financial hardship, long term oxygen use, having anxiety and de-
pression, and having a reduced baseline health-related quality of
life (Boutou 2014; Cassidy 2014; Fischer 2007; Hayton 2013;
Hogg 2012; Keating 2011; McNaughton 2016; Sabit 2008).
Description of the intervention
The purpose of this review is to focus on interventions to improve
referral, uptake, and adherence to pulmonary rehabilitation by
COPD patients, which is already recommended as an effective
service.
Interventions identified in scoping reviews have identified that in-
creasing HCP knowledge, and support to COPDpatients to man-
age co-morbidities, such as anxiety and depression, improved pa-
tient uptake to PR (Hardy 2014). A quasi-randomised trial sought
to increase patient empowerment by using tablet devices with a
personal training diary. Investigators observed improvements in
PR adherence in this intervention group compared with usual care
(Ringbaek 2016).
Interventions may use a variety of delivery platforms, including
digital technologies, avatar-based technologies and videos, ormore
traditional, written information, paying attention to the verbal
and written language used (Johnston 2013; Williams 2011). The
use of ‘lay’ advocates, such as ‘expert patients’ may also play a key
role.
How the intervention might work
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The intervention may use a variety of direct or indirect behaviour
change approaches, either separately or in combination, targeted
at each step or audience. The intervention may target the patient,
their HCP, partner, family members, caregivers, friends, or a com-
bination.
Within the behaviour change approaches, it is likely the interven-
tions will seek to address capability, opportunity, or motivation is-
sues within each of the specified participant groups (Michie 2013).
This may, for example, include increasing the opportunities to dis-
cuss or access PR programmes; it may also include strategic inter-
ventions, which enhance referral processes or increase awareness
of PR programmes and their benefits.
Why it is important to do this review
COPD is an increasing global public health issue, with a high
burden of morbidity and mortality (Lozano 2012; Murray 2015).
PR is a clinically effective and cost effective intervention that can
reduce mortality and improve prognosis.
However, referral to pulmonary rehabilitation programmes, and
uptake and adherence rates are universally low. Interventions to
tackle each of these outcomes will benefit patients’ physical and
psychological well-being, and reduce the use of unplanned and
emergency healthcare services.
There is only one similar systematic review that has been pub-
lished, which investigated interventions that sought to improve
the uptake and completion of pulmonary rehabilitation in COPD
(Jones 2017). This systematic review included only randomised
controlled trials, of which there was only one (Ringbaek 2016).
They concluded that they could not make any recommendations
for practice. Three UK trials are currently underway, and there are
non-randomised studies available, which will inform the evidence
base and warrant inclusion.
There is also a systematic review that investigated interventions
that increased uptake and adherence to cardiac rehabilitation for
patients with coronary heart disease, including heart failure. This
review reported limited evidence supporting intervention effec-
tiveness within this field (Karmali 2014). Similar to Jones 2017,
this systematic review only included RCTs.
Given the ongoing studies within in the pulmonary rehabilitation
field, and the lack of evidence reported by previous systematic
reviews that only included RCTs, this proposed systematic review,
which will be regularly updated to include new evidence and will
have clinical benefit for those with COPD and their caregivers.
O B J E C T I V E S
To determine the effectiveness of interventions to increase patient
referral, uptake, and adherence to pulmonary rehabilitation pro-
grammes, for patients with COPD.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We anticipate that there will be limited trials available, therefore,
we will include a broad range of study designs including: ran-
domised controlled trials (RCT; individual or cluster-level) and
observational studies, such as non-randomised controlled trials
(including controlled before-and-after studies and non-controlled,
before-and-after studies). We will include studies reported in full
text, those published as an abstract only, and unpublished data.
We will not apply any restrictions.
Types of participants
Inclusion criteria
Interventions to improve referral, uptake, and adherence rates may
be applied to healthcare professionals or patients, partners, care-
givers, family, or friends of the COPD patient. Therefore, we will
include studies in which the population is either:
1. Healthcare practitioners (of any age) who care for patients with
either stable or acute COPD, in all healthcare settings.
Or:
2. Adult participants (at least 18 years of age) who have a primary
diagnosis of COPD, defined with or without spirometric confir-
mation. We will include studies in which the participants have
any stage of COPD, with either stable disease or post-acute exac-
erbations, and who may have singular or multiple co-morbidities.
There will be no upper age limit.
Or:
3. Partners, caregivers, family, or friends (of any age), of theCOPD
patient, who may influence referral, uptake, or adherence to pul-
monary rehabilitation.
Exclusion criteria
We will exclude studies in which the focus of the study is on
participants receiving PR with the following primary diagnoses:
asthma, bronchiectasis, lung cancer, interstitial lung disease (ILD),
and congestive cardiac failure.
We will exclude interventions that are designed to target other
programmes, such as maintenance pulmonary rehabilitation pro-
grammes.
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Types of interventions
Interventions will be eligible if they aim to increase referral to,
uptake of, or adherence to any type of PR programme.
Potential comparators could be usual care, or any concurrent con-
trol group that was not receiving an intervention that aimed to
improve referral, uptake, or adherence to PR, or alternative inter-
vention to improve referral/uptake/adherence.
Types of outcome measures
Primary outcomes
1. Referral to pulmonary rehabilitations programmes (as
measured by referral sent or received)
2. Attendance at pulmonary rehabilitation programme
assessment
3. Attendance at start of pulmonary rehabilitation programme
4. Adherance to pulmonary rehabilitation programme (as
specified by study reports, but usually percent % of sessions
attended)
We will present outcomes as proportions.
Rationale. In order to access and enrol in PR, patients are initially
referred by a HCP, or in some circumstances, the patient may self-
refer. Attending a PR assessment is the next step, which if suc-
cessful, is followed by an opportunity to start a PR programme.
Adequate attendance at PR programmes is essential in order to
gain clinical and psychosocial benefits, however, the literature in-
forms us that these steps are areas of weakness in PR recruitment
and retention. Interventions designed to increase uptake and sus-
tainability at each stage are emerging. Identifying those that are
effective is a key aim of the systematic review.
Secondary outcomes
There are no secondary outcome measures for this review.
Search methods for identification of studies
Electronic searches
We will search for randomised controlled trials in the Cochrane
Airways Trials Register, which is maintained by the Information
Specialist for the Group. The Cochrane Airways Trials Register
contains studies identified from several sources (see Appendix 1
for details). We will conduct additional searches of the following
databases, using appropriate search terms to identify both ran-
domised and non-randomised trials:
1. Cochrane Central Register of Controlled Trials through the
Cochrane Register of Studies Online (CENTRAL; search date) ;
2. MEDLINE Ovid (1946 to search date);
3. Embase Ovid (1974 to search date);
4. CINAHL EBSCO (Cumulative Index to Nursing and
Allied Health Literature; all years to search date);
5. PEDro (Physiotherapy Evidence Database; search date)
We have described the proposed CENTRAL and MEDLINE
search strategies in Appendix 2. We will adapt them for the other
databases. We will search all databases from their inception to the
present, and there will be no restriction on language of publica-
tion. We will search handsearched conference abstracts and grey
literature through the CENTRAL database and the Cochrane Air-
ways Trials Register.
We will search the following trials registries:
1. UK Clinical Trials Gateway (ukctg.nihr.ac.uk)
2. US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov (www.clinicaltrials.gov/)
3. World Health Organization International Clinical Trials
Registry Platform (ICTRP; apps.who.int/trialsearch/)
Searching other resources
We will check the reference lists of all primary studies and review
articles for additional references.We will search relevant manufac-
turers’ websites for study information.
We will search for errata or retractions from included studies pub-
lished in full text on PubMed and report the date this was done
in the review.
Data collection and analysis
Selection of studies
Two review authors (JY and RJ) will independently screen the ti-
tles and abstracts of the search results and code them as ’retrieve’
(eligible or potentially eligible or unclear) or ’do not retrieve’. We
will retrieve the full-text study reports of all potentially eligible
studies, and two review authors (JY and RA) will independently
screen them for inclusion, recording the reasons for exclusion of
ineligible studies. We will resolve any disagreement through dis-
cussion, or if required, we will consult a third review author (PA).
We will identify and exclude duplicates and collate multiple re-
ports of the same study, so that each study, rather than each report,
is the unit of interest in the review. We will record the selection
process in sufficient detail to complete a PRISMA flow diagram
and ’Characteristics of excluded studies’ table (Moher 2009).
Data extraction and management
We will use a pre-designed data collection form for these study
characteristics and outcome data, which will be piloted on at least
one study in the review.
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1. Methods: study design, aim of study, total duration of
study, details of any ’run-in’ period, number of study centres and
location, study setting, withdrawals, and date of study. Study
inclusion and exclusion criteria
2. COPD patients: N, mean age, age range, gender, severity of
condition, diagnostic criteria, baseline lung function, smoking
history, medication, prior history of PR
3. Healthcare practitioner: N, mean age, gender, job role,
length of time in job role, contracted hours in job role, prior
academic experience, knowledge of and experience with PR
4. Interventions: type of behaviour change intervention,
duration of intervention and comparator, description of target
PR service
5. Outcomes: primary and secondary outcomes specified and
collected, and time points reported
6. Notes: funding for studies, and notable conflicts of interest
of trial authors.
Two review authors (JY and RJ) will independently extract out-
come data from included studies. We will note in the ’Character-
istics of included studies’ table if outcome data were not reported
in a usable way. We will resolve disagreements by consensus, or
by involving a third review author (PA). One review author (JY)
will transfer data into the Review Manager 5 file (RevMan 2014).
We will double-check that data are entered correctly by comparing
the data presented in the systematic review with the study reports.
A second review author (AE) will spot-check study characteristics
for accuracy against the study report.
Assessment of risk of bias in included studies
Two review authors (JY and RJ) will independently assess risk
of bias for each study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will resolve any disagreements by discussion or by involving
another author (PA). We will assess the risk of bias according to
the following domains:
1. random sequence generation;
2. allocation concealment;
3. blinding of participants and personnel;
4. blinding of outcome assessment;
5. incomplete outcome data;
6. selective outcome reporting;
7. other bias.
We will judge each potential source of bias as high, low, or un-
clear, and provide a quote from the study report and a justification
for our judgement in the ’Risk of bias’ table. We will summarise
the risk of bias judgements across different studies for each of the
domains listed. We will consider blinding separately for different
key outcomes where necessary (e.g. for unblinded outcome assess-
ment, risk of bias for objectively recorded PR attendance may be
different than for patient-reported attendance). Where informa-
tion on risk of bias relates to unpublished data or correspondence
with a trialist, we will note this in the ’Risk of bias’ table.
When considering treatment effects, we will take into account the
risk of bias for the studies that contribute to that outcome.
Methodological quality or risk of bias for non-randomised studies
will be assessed using the ROBINS-I tool (Sterne 2016).
When including non-randomised studies, we will assess whether
the authors have accounted for potential confounding factors in-
cluding characteristics of the patients (e.g. age, sex, ethnicity,
smoking status, severity of disease, co-morbidities, prior atten-
dance at PR, caring responsibilities, distance from programme)
and characteristics of the healthcare professionals (type, experi-
ence, age, academic history).
Assessment of bias in conducting the systematic
review
We will conduct the review according to this published protocol,
and justify any deviations from it in the ’Differences between
protocol and review’ section of the systematic review.
Measures of treatment effect
We will analyse dichotomous data as odds ratios (OR), and con-
tinuous data as the mean difference (MD) or standardised mean
difference (SMD).
We will undertake meta-analyses of RCTs and CCTs only when
this is meaningful; that is, if the treatments, participants, out-
comes, and the underlying clinical question are similar enough for
pooling to make sense.
We will use RevMan 5 software to calculate pooled effect sizes, to
test for heterogeneity, and to perform subgroup analysis (RevMan
2014).
We will only combine RCTs and CCTs if there is minimal clinical
and methodological diversity between the controlled studies.
If there is large heterogeneity, we will explore reasons for it, in-
cluding undertaking subgroup analyses of the RCTs and CCTs
separately.
Wewill use a narrative format to describe skeweddata (for example,
as medians and interquartile ranges for each group).
For non-controlled before and after studies we intend to describe
the presence of the study and describe the results together with
caveats about the lack of control group.
It is likely that only end point studies will be available.
Unit of analysis issues
The unit of analysis will be the patient, and/or the healthcare
practitioner. We will only meta-analyse data from cluster-RCTs
if the available data have been adjusted (or can be adjusted), to
account for the clustering. For cluster-randomised trials, we will
make adjustments to the sample sizes for each intervention, based
on the method described in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011).
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Dealing with missing data
We will contact investigators or study sponsors to verify key study
characteristics and obtain missing numerical outcome data where
needed (e.g. when a study is identified as an abstract only). When
this is not possible, and the missing data are thought to introduce
serious bias, we will take this into consideration in the GRADE
rating for affected outcomes.
When we identify relevant studies of mixed populations with no
subgroup data, we will contact the study authors to request them.
If we are still unable to acquire these data, and if less than 80%
of the participants are from the population of interest, we will
describe these studies in a narrative format, but exclude them from
meta-analyses.
Assessment of heterogeneity
If appropriate we will use the I² statistic to measure heterogeneity
among the studies in each analysis. We will consider an I2 value
greater than 50% to indicate substantial statistical heterogeneity,
we will report it and explore the possible causes by pre-specified
subgroup analysis (see below).
Assessment of reporting biases
If we are able to pool more than 10 studies, we will create and
examine a funnel plot to explore possible small study and publi-
cation biases.
Data synthesis
We will use a random-effects model and perform a sensitivity
analysis with a fixed-effect model (if appropriate).
’Summary of findings’ table
We will create a ’Summary of findings’ table with the following
outcomes: referral to pulmonary rehabilitations programmes, at-
tendance at PR programme assessment, attendance at start of PR
programme, and attendance for the duration of PR programme.
We will use the five GRADE considerations (risk of bias, indi-
rectness, consistency of effect, imprecision, and publication bias)
to assess the quality of a body of evidence as it relates to the
studies that contribute data for the pre-specified outcomes. We
will use the methods and recommendations described in Section
8.5 and Chapter 12 of the Cochrane Handbook for Systematic Re-
views of Interventions (Higgins 2011), and GRADEpro software
(GRADEpro GDT). We will justify all decisions to downgrade
the quality of studies in footnotes, and we will make comments to
aid the reader’s understanding of the review where necessary.
Subgroup analysis and investigation of heterogeneity
We plan to carry out the following subgroup analyses where pos-
sible:
1.Type of referring healthcare practitioner (nurse, doctor, other)
Rationale: the type of healthcare practitioner could influence
whether patients are referred, and the likelihood of uptake and
adherence after referral.
2. Origin of referral (self, community, hospital)
Rationale. Motivation for adherence and completion may vary
according to who made the referral.
3.Pulmonary rehabilitation programme setting (home versus cen-
tre-based)
Rationale. Perceived convenience of attending has been high-
lighted as a barrier to attendance in qualitative studies. Therefore,
the setting could influence uptake, adherence, or completion.
4.Patient age (up to 65 years, over 65 years)
Rationale. Patient age and working status are reported to be an
influencing characteristic, particularly in adherence. The age cut-
off is based on approximate age for retirement.
5. COPD severity (as determined by stable disease or post-exac-
erbation)
Rationale. Motivation to attend and complete may differ accord-
ing to whether the patient has had a recent exacerbation.
We will use the following outcomes in subgroup analyses:
1. Referral to PR programmes (as measured by study reports);
2. Attendance at PR programme assessment (as measured by
study reports);
3. Attendance at start of PR programmes (as measured by
study reports);
4. Adherence to PR programmes (as measured by study
reports).
We will use the formal test for subgroup interactions in Review
Manager 5 (RevMan 2014).
Sensitivity analysis
We will undertake sensitivity analyses, where possible to
• compare the results from a fixed-effect model with the
random-effects models;
• restrict the analyses to those with an active comparator only;
• if only non-randomised controlled clinical trials are
available, remove studies that are at ‘serious’ or ‘critical’ risk of
bias, according to the ROBINS-I tool
We will exclude RCT studies with high risk of bias (two or more
domains judged to be at high risk of bias).
A C K N OW L E D G E M E N T S
The Background and Methods sections of this protocol are based
on a standard template used by Cochrane Airways.
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Appendix 1. Sources searched for the Cochrane Airways Trials Register
Electronic searches: core databases
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Handsearches: core respiratory conference abstracts
Conference Years searched
AmericanAcademyofAllergy, Asthma and Immunology (AAAAI) 2001 onwards
American Thoracic Society (ATS) 2001 onwards
Asia Pacific Society of Respirology (APSR) 2004 onwards
British Thoracic Society Winter Meeting (BTS) 2000 onwards
Chest Meeting 2003 onwards
European Respiratory Society (ERS) 1992, 1994, 2000 onwards
International PrimaryCareRespiratoryGroupCongress (IPCRG) 2002 onwards
Thoracic Society of Australia and New Zealand (TSANZ) 1999 onwards
Appendix 2. Database search strategies
CENTRAL (Cochrane Register of Studies Online)
#1 MESH DESCRIPTOR Pulmonary Disease, Chronic Obstructive EXPLODE ALL TREES
#2 MESH DESCRIPTOR Bronchitis, Chronic
#3 (obstruct*) near3 (pulmonary or lung* or airway* or airflow* or bronch* or respirat*)
#4 (COPD OR COAD OR COBD OR AECOPD):TI,AB,KW
#5 #1 OR #2 OR #3 OR #4
#6 MESH DESCRIPTOR Rehabilitation EXPLODE ALL TREES
#7 MESH DESCRIPTOR Respiratory Therapy EXPLODE ALL TREES
#8 MESH DESCRIPTOR Physical Therapy Modalities EXPLODE ALL TREES
#9 (rehabilitat* or fitness* or exercis* or train* or physiotherap* or (physical* NEXT therap*)):TI,AB,KY
#10 #6 OR #7 OR #8 OR #9
#11 MESH DESCRIPTOR Patient Compliance EXPLODE ALL TREES
#12 MESH DESCRIPTOR Patient Acceptance of Health Care EXPLODE ALL TREES
#13 MESH DESCRIPTOR Patient Dropouts
#14 (adhere* or nonadhere* or non-adhere*):TI,AB,KY
#15 (complet* or complian* or noncomplian* or non-complian*):TI,AB,KY
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#21 MESH DESCRIPTOR Referral and Consultation EXPLODE ALL TREES
#22 MESH DESCRIPTOR Health Promotion EXPLODE ALL TREES




#27 (uptake or up-take):TI,AB,KY
#28 (increase* NEAR participat*):TI,AB,KY
#29 attend*:TI,AB,KY
#30 engage*:TI,AB,KY
#31 #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25
OR #26 OR #27 OR #28 OR #29 OR #30
#32 #5 AND #10 AND #31
MEDLINE Ovid
1. exp Pulmonary Disease, Chronic Obstructive/
2. Bronchitis, Chronic/
3. (obstruct$ adj3 (pulmonary or lung$ or airway$ or airflow$ or bronch$ or respirat$)).tw.
4. (COPD or COAD or COBD or AECOPD).tw.
5. or/1-4
6. exp Rehabilitation/
7. exp Respiratory Therapy/
8. exp Physical Therapy Modalities/
9. (rehabilitat$ or fitness$ or exercis$ or train$ or physiotherap$ or physical$ NEXT therap$).tw.
10. or/6-9
11. exp Patient Compliance/
12. exp Patient Acceptance of Health Care/
13. Patient Dropouts/
14. (adhere$ or nonadhere$ or non-adhere$).tw.
15. (complet$ orcomplian$ or noncomplian$ or non-complian$).tw.





21. exp Health Promotion/
22. exp “Referral and Consultation”/




27. (uptake or up-take).tw.




32. 5 and 10 and 31
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33. (controlled clinical trial or randomized controlled trial).pt.







41. cohort studies/ or longitudinal studies/ or follow-up studies/ or prospective studies/ or retrospective studies/ or cohort.ti,ab. or
longitudinal.ti,ab. or prospective.ti,ab. or retrospective.ti,ab.
42. Case-Control Studies/ or Control Groups/ orMatched-Pair Analysis/ or ((case* adj5 control*) or (case adj3 comparison*) or control
group*).ti,ab,kw.
43. comparative study.pt.
44. (pre test or pretest or post test or posttest or preintervention or postintervention).tw.
45. (case$ adj3 series).tw.
46. or/41-45
47. 40 or 56
48. 32 and 47
49. Animals/
50. Humans/
51. 49 not (49 and 50)
52. 48 not 51
C O N T R I B U T I O N S O F A U T H O R S
JY will co-ordinate the review; design search strategies in collaboration with Cochrane Airways Group’s Information Specialist; will
undertake study selection, data extraction, and entry into RevMan 5; will contribute to data analysis and interpretation of data.
RJ will undertake study selection, data extraction, and entry into RevMan 5; will contribute to data analysis and interpretation of data.
AE will spot-check study characteristics for accuracy against the study report and will contribute to the interpretation of data.
PA will be the third reviewer of included studies in the case of uncertainty. PA will also provide a clinical perspective and general advice
on the review.
KJ will provide a methodological perspective, a clinical perspective, and general advice on the review; KJ will be the third reviewer of
’risk of bias’ issues in the case of uncertainty.
All authors contributed to the reading, writing, and approval of this protocol.
The review will be updated by all authors.
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